Fosca Lc, Bardas Ca, Mosonyi N, M. A, O. D., Tomoia G
{"title":"The Failure Incidence of Trochanteric Fracture Fixation Using Gamma Nail or PFNA","authors":"Fosca Lc, Bardas Ca, Mosonyi N, M. A, O. D., Tomoia G","doi":"10.26420/gerontolgeriatrres.2021.1066","DOIUrl":"https://doi.org/10.26420/gerontolgeriatrres.2021.1066","url":null,"abstract":"Aim: The importance of trochanteric fractures treatment consists in a relatively high frequency, especially in elderly patients. There is no “gold standard” implant for treating this type of fracture and various complications might occur in any particular case. The aim of this study was to evaluate the rates of implant related complications in patients treated for trochanteric fractures using two types of implants (Gamma 3® and PFNA®). The secondary objective was to assess the possible correlation between complication rates and technical parameters of insertion. Methods: Patients who met inclusion criteria were selected retrospectively between September 2018 and December 2020. Results: Ninety-five percent of patients were treated using a Gamma 3® nail while only 5% of them were treated using a PFNA® implant. Following AO classification, 60% of the patients presented an A1.3 fracture type and 29% presented an A1.2 fracture type. The global complication rate was 12.33% while specific incidence for each category of complications assessed in this group was as follows: 7.67% lateral protrusion of the lag screw, 3.67% cut-out, 0.67% impossibility of distal locking and 0.33% migration of distal locking screw. A significant difference p=0.018 was found between postoperative neck-shaft angles of the two groups of patients treated with the two types of implants. Conclusion: Use of Gamma 3® nails in trochanteric fractures obtains a degree of reduction closer to the physiological neck-shaft angle compared to the PFNA® implant. The most frequent complication type in our group was lateral protrusion of the lag screw followed by cut-out.","PeriodicalId":310319,"journal":{"name":"Gerontology & Geriatrics: Research","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115639763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Progress with Legalising Physician Assisted Dying in England","authors":"E. T.","doi":"10.26420/gerontolgeriatrres.2021.1065","DOIUrl":"https://doi.org/10.26420/gerontolgeriatrres.2021.1065","url":null,"abstract":"I became interested in helping with this in 2001. This occurred as a result of my friendship with Lord Joffe, who had introduced 2 Bills in the House of Lords, neither of which succeeded. I was particularly attracted by the concept of having the option of control over when and how I would die if I were suffering uncontrollably at the end of a terminal illness. At that time the majority of the medical profession was against this, so I joined Dignity in Dying and was given the task of trying to help doctors reach a more positive view about the benefits associated with physician assisted dying. To this end we formed a subcommittee, “Healthcare Professionals for Assisted Dying”. We organized lectures and debates around the regions and brought our message, when given the chance, to the Annual Representatives Meeting of the British Medical Association. Progress has been slow but rewarding and at the last ARM a vote for neutrality rather than opposition was passed. This has also been adopted by several of the main Royal Colleges of medicine.","PeriodicalId":310319,"journal":{"name":"Gerontology & Geriatrics: Research","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128641885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mitochondrial Dysfunction in Alzheimer’s Disease and Possible Therapeutic Targets to Prevent Progression of Alzheimer’s Disease","authors":"D. Sk","doi":"10.26420/gerontolgeriatrres.2021.1064","DOIUrl":"https://doi.org/10.26420/gerontolgeriatrres.2021.1064","url":null,"abstract":"Alzheimer’s Disease (AD) is the most frequent cause of dementia in aged population. Till now, there is no effective treatment for AD. Now various studies have kinked AD to mitochondrial dysfunction, due to accumulation of Aβaggregates, neurofibrillary tangles, cholinergic transmission, oxidative stress and neuroinflammation causing neurodegeneration and cognitive decline seen in AD. Here in this article, how the mitochondrial dysfunction/dynamics are involved in the pathogenesis of cognitive decline seen in cases of AD and various therapeutics targeted against mitochondrial dysfunctions are described, thereby causing a ray of hope for preventing progression of AD.","PeriodicalId":310319,"journal":{"name":"Gerontology & Geriatrics: Research","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121335622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}